Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Neurology · Muscle Glycogen Storage Disease

Managing Muscle GSDs: Pompe and McArdle Disease

At a Glance

Muscle GSDs like Pompe and McArdle disease require distinct management strategies. Pompe disease is treated with early Enzyme Replacement Therapy to prevent muscle damage, while McArdle disease requires careful exercise pacing and pre-activity carbohydrates to prevent severe muscle breakdown.

While hepatic GSDs affect blood sugar, Muscle GSDs primarily impact the body’s ability to move and breathe. Pompe Disease and McArdle Disease are the two most well-known forms, and though they both affect the muscles, their biology and management are very different.

Pompe Disease (GSD II): The Storage Challenge

Pompe disease is unique because it is both a GSD and a lysosomal storage disorder. In this condition, the body lacks an enzyme called acid alpha-glucosidase (GAA), which is needed to break down glycogen inside the “recycling centers” of cells (lysosomes) [1][2]. Without this enzyme, glycogen builds up and eventually destroys muscle fibers.

Two Forms of Pompe

  • Infantile-Onset (IOPD): This is the most severe form, appearing within the first year of life [3]. The hallmark is hypertrophic cardiomyopathy (a severely thickened heart), along with extreme muscle weakness and breathing difficulties [4][5].
  • Late-Onset (LOPD): This form can appear at any age, from childhood to late adulthood [4]. It typically doesn’t involve the heart but causes progressive weakness in the legs and hips (limb-girdle weakness) and can lead to respiratory failure as the diaphragm weakens [6][7].

The Role of ERT

The cornerstone of treatment is Enzyme Replacement Therapy (ERT), where the missing enzyme is given through an IV infusion [8].

  • Early Initiation is Vital: Starting ERT as early as possible—ideally before symptoms even start—is critical to prevent irreversible muscle damage and improve survival [9][10].
  • Next-Gen Options: Newer versions of ERT, such as avalglucosidase alfa, are designed to target muscle cells more effectively, potentially improving motor and breathing outcomes [11][12].

McArdle Disease (GSD V): The Energy Shortage

McArdle disease is the opposite of Pompe; the muscles can’t use the glycogen they have because they lack the enzyme myophosphorylase (from the PYGM gene) [13][14]. This creates a massive energy gap during the first few minutes of exercise.

The “Second Wind” Phenomenon

Patients with McArdle disease experience a unique biological event called the “second wind.”

  1. The Crisis: For the first 7–10 minutes of activity, patients feel intense fatigue, high heart rate, and muscle pain because they cannot use muscle glycogen for fuel [15][16]. During this crisis phase, it is vital to rest or pause—do not try to “push through” the pain, as this can cause severe muscle damage.
  2. The Shift: After about 10 minutes, the body switches to using alternative fuels from the blood (glucose and fatty acids) [17][18].
  3. The Relief: Suddenly, the pain vanishes, the heart rate drops, and the patient can continue moderate activity (like walking) with much more ease [16][19].

Managing the Muscle Risk

  • Fueling Up: Consuming a small amount of carbohydrates (like 30-40g of sucrose) about 30–40 minutes before exercise can provide the blood sugar needed to help bypass the initial energy crisis [17].
  • Avoiding Rhabdomyolysis: Intense “burst” activities (like sprinting) or isometric exercises (like heavy lifting) can cause rhabdomyolysis—a dangerous breakdown of muscle tissue that can lead to kidney damage [20][21]. A primary warning sign is dark, tea- or cola-colored urine. If this occurs, seek emergency medical care immediately for IV hydration. Pacing is the most important skill for a McArdle patient to learn [22].

Common questions in this guide

What is the second wind phenomenon in McArdle disease?
The second wind is a unique biological shift in McArdle disease. During the first 10 minutes of exercise, patients feel intense fatigue and muscle pain. Afterward, the body switches to using alternative fuels from the blood, causing the pain to vanish so moderate activity can continue.
Why is early Enzyme Replacement Therapy (ERT) important for Pompe disease?
Starting ERT as early as possible replaces the missing GAA enzyme needed to break down glycogen inside cells. Prompt treatment is critical to prevent irreversible muscle damage and improve both breathing and motor outcomes.
What are the signs of rhabdomyolysis in McArdle disease?
Rhabdomyolysis is a dangerous breakdown of muscle tissue caused by intense or isometric exercise. A primary warning sign is dark, tea- or cola-colored urine, which requires immediate emergency medical care and IV hydration to protect the kidneys.
How can I prevent the initial energy crisis before exercising with McArdle disease?
Consuming a small amount of simple carbohydrates, such as 30 to 40 grams of sucrose, about 30 to 40 minutes before activity provides your blood with the sugar needed to help bypass the initial energy shortage.
What is the difference between infantile and late-onset Pompe disease?
Infantile-onset is the most severe form, appearing in the first year of life with extreme muscle weakness and a severely thickened heart. Late-onset can appear at any age and typically causes progressive weakness in the legs, hips, and diaphragm without affecting the heart.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.For Pompe: Has the CRIM (Cross-Reactive Immunologic Material) status been determined, and how does that affect our ERT plan?
  2. 2.How frequently should we monitor heart and lung function as the disease progresses?
  3. 3.For McArdle: What is our specific emergency hydration protocol if rhabdomyolysis occurs?
  4. 4.Can you recommend a physical therapist who has experience specifically with muscle-focused GSDs?
  5. 5.Should we consider the newer 'next-generation' ERT options like avalglucosidase alfa?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Pompe disease: how to solve many problems with one solution.

    Puertollano R, Raben N

    Annals of translational medicine 2018; (6(15)):313 doi:10.21037/atm.2018.06.52.

    PMID: 30211201
  2. 2

    Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.

    Meena NK, Raben N

    Biomolecules 2020; (10(9)) doi:10.3390/biom10091339.

    PMID: 32962155
  3. 3

    Greater Efficacy of Avalglucosidase vs Alglucosidase Alfa in Adult Pompe Disease? The Jury Is Still Out.

    de Visser M, Argov Z

    Neurology 2022; (99(5)):183-184 doi:10.1212/WNL.0000000000200821.

    PMID: 35618439
  4. 4

    Clinical and Genetic Aspects of Juvenile Onset Pompe Disease.

    Holzwarth J, Minopoli N, Pfrimmer C, et al.

    Neuropediatrics 2022; (53(1)):39-45 doi:10.1055/s-0041-1735250.

    PMID: 34852371
  5. 5

    Infantile Pompe disease with intrauterine onset: a case report and literature review.

    Xi H, Li X, Ma L, et al.

    Italian journal of pediatrics 2022; (48(1)):187 doi:10.1186/s13052-022-01379-3.

    PMID: 36411466
  6. 6

    Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease.

    Winkler M, von Landenberg C, Kuchenbecker K, et al.

    Neuromuscular disorders : NMD 2022; (32(3)):195-205 doi:10.1016/j.nmd.2022.01.001.

    PMID: 35120758
  7. 7

    Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).

    Ripolone M, Violano R, Ronchi D, et al.

    Neuropathology and applied neurobiology 2018; (44(5)):449-462 doi:10.1111/nan.12414.

    PMID: 28574618
  8. 8

    Defect in degradation of glycogenin-exposed residual glycogen in lysosomes is the fundamental pathomechanism of Pompe disease.

    Zhang N, Liu F, Zhao Y, et al.

    The Journal of pathology 2024; (263(1)):8-21 doi:10.1002/path.6255.

    PMID: 38332735
  9. 9

    Infantile-onset Pompe disease: Diagnosis and management.

    Bay LB, Denzler I, Durand C, et al.

    Archivos argentinos de pediatria 2019; (117(4)):271-278 doi:10.5546/aap.2019.eng.271.

    PMID: 31339275
  10. 10

    Evaluation of Experienced Clinical Events in Pompe Disease Based on Real-life Data.

    Erdem Karapınar F, Yazıcı H, Yoldaş Çelik M, et al.

    Neuropediatrics 2026; (57(2)):121-130 doi:10.1055/a-2777-2932.

    PMID: 41453391
  11. 11

    Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.

    Diaz-Manera J, Kishnani PS, Kushlaf H, et al.

    The Lancet. Neurology 2021; (20(12)):1012-1026 doi:10.1016/S1474-4422(21)00241-6.

    PMID: 34800399
  12. 12

    Quantitative Systems Pharmacology-Based Digital Twins Approach Supplements Clinical Trial Data for Enzyme Replacement Therapies in Pompe Disease.

    Kaddi C, Tao M, Bergeler S, et al.

    Clinical pharmacology and therapeutics 2025; (117(2)):579-588 doi:10.1002/cpt.3498.

    PMID: 39632463
  13. 13

    Metabolic aspects of glycogenolysis with special attention to McArdle disease.

    Stefanik E, Dubińska-Magiera M, Lewandowski D, et al.

    Molecular genetics and metabolism 2024; (142(4)):108532 doi:10.1016/j.ymgme.2024.108532.

    PMID: 39018613
  14. 14

    Novel variant in the PYGM gene causing late-onset limb-girdle myopathy, ptosis, and camptocormia.

    Chéraud C, Froissart R, Lannes B, Echaniz-Laguna A

    Muscle & nerve 2018; (57(1)):157-160 doi:10.1002/mus.25588.

    PMID: 28120463
  15. 15

    Searching for Clues in the Diagnosis of McArdle Disease.

    Uysal SP, Li G, Claytor BR

    Cureus 2025; (17(6)):e86793 doi:10.7759/cureus.86793.

    PMID: 40718250
  16. 16

    The Second Wind in McArdle Patients: Fitness Matters.

    Salazar-Martínez E, Santalla A, Valenzuela PL, et al.

    Frontiers in physiology 2021; (12()):744632 doi:10.3389/fphys.2021.744632.

    PMID: 34721068
  17. 17

    Acute ketone supplementation in the absence of muscle glycogen utilization: Insights from McArdle disease.

    Valenzuela PL, Santalla A, Alejo LB, et al.

    Clinical nutrition (Edinburgh, Scotland) 2024; (43(3)):692-700 doi:10.1016/j.clnu.2024.01.026.

    PMID: 38320460
  18. 18

    Muscle glycogen unavailability and fat oxidation rate during exercise: Insights from McArdle disease.

    Rodriguez-Lopez C, Santalla A, Valenzuela PL, et al.

    The Journal of physiology 2023; (601(3)):551-566 doi:10.1113/JP283743.

    PMID: 36370371
  19. 19

    Exercise Intolerance in McArdle Disease: A Role for Cardiac Impairment? A Preliminary Study in Humans and Mice.

    Santos-Lozano A, Boraita A, Valenzuela PL, et al.

    Medicine and science in sports and exercise 2024; (56(12)):2241-2255 doi:10.1249/MSS.0000000000003529.

    PMID: 39160758
  20. 20

    Repeatedly in Rhabdomyolysis.

    Gooch C, Dean SJ, Marzullo L

    Pediatric emergency care 2021; (37(12)):e1759-e1760 doi:10.1097/PEC.0000000000002079.

    PMID: 32205805
  21. 21

    McArdle disease causing rhabdomyolysis following vaginal delivery.

    McMillan BM, Hirshberg JS, Cosgrove SC

    Anaesthesia reports 2019; (7(2)):73-75 doi:10.1002/anr3.12022.

    PMID: 32051955
  22. 22

    Improvement of Symptoms in a Patient With Glycogen Storage Disease Through Nutritional Guidance and Exercise Therapy.

    Morita T, Murakami T, Okamura E, et al.

    JCEM case reports 2025; (3(11)):luaf217 doi:10.1210/jcemcr/luaf217.

    PMID: 41018174

This page provides educational information on managing muscle GSDs like Pompe and McArdle disease. It does not replace professional medical advice from your geneticist, neurologist, or healthcare team.

Get notified when new evidence is published on Glycogen storage disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.